Data / Drug companies / Chartwell RX, LLC
Chartwell RX, LLC: 578 products in the FDA NDC directory, labeler code 62135
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Chartwell RX, LLC (labeler code 62135) lists 578 products in the FDA National Drug Code Directory, covering 234 finished drugs by generic name. By type: 578 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 17, 2026.
The request: Watch Chartwell RX, LLC (FDA labeler code 62135): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 62135
- Products in commercial distribution
- 578
- Packages
- 829
- Finished drugs by generic name
- 234
- Prescription products
- 578
- Over the counter products
- 0
- Controlled substance products
- Schedule II 1, Schedule III 2, Schedule IV 42, Schedule V 6
- Flagged as original packager
- 545 of 545 products that carry the flag
- Started marketing in the last 12 months
- 8
- Earliest marketing start
- April 14, 1971
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 531 | 91.9% |
| Other unapproved drugs | 32 | 5.5% |
| Authorized generics (NDA) | 14 | 2.4% |
| New drug applications (NDA) | 1 | 0.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 578 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 233 | 40.3% |
| Tablet, film coated | 95 | 16.4% |
| Capsule | 90 | 15.6% |
| Solution | 55 | 9.5% |
| Tablet, extended release | 19 | 3.3% |
| Suspension | 16 | 2.8% |
| Powder, for suspension | 15 | 2.6% |
| Tablet, film coated, extended release | 7 | 1.2% |
| Tablet, orally disintegrating | 7 | 1.2% |
| Tablet, chewable | 6 | 1% |
| Syrup | 6 | 1% |
| Tablet, sugar coated | 5 | 0.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Phenobarbital | 62135-558 | Tablet | Other unapproved drugs | August 17, 2026 |
| Phenobarbital | 62135-557 | Tablet | Other unapproved drugs | August 17, 2026 |
| Phenobarbital | 62135-554 | Tablet | Other unapproved drugs | August 17, 2026 |
| Phenobarbital | 62135-539 | Tablet | Other unapproved drugs | August 17, 2026 |
| Phenobarbital | 62135-519 | Tablet | Other unapproved drugs | August 17, 2026 |
| Phenobarbital | 62135-515 | Tablet | Other unapproved drugs | August 17, 2026 |
| Phenobarbital | 62135-514 | Tablet | Other unapproved drugs | August 17, 2026 |
| Phenobarbital | 62135-510 | Tablet | Other unapproved drugs | August 17, 2026 |
| Sucralfate | 62135-106 | Suspension | Generic drugs (ANDA) | April 14, 2025 |
| Phenobarbital | 62135-962 | Solution | Other unapproved drugs | February 13, 2025 |
| Pravastatin Sodium | 62135-850 | Tablet, film coated | Generic drugs (ANDA) | September 26, 2024 |
| Pravastatin Sodium | 62135-849 | Tablet, film coated | Generic drugs (ANDA) | September 26, 2024 |
| Pravastatin Sodium | 62135-848 | Tablet, film coated | Generic drugs (ANDA) | September 26, 2024 |
| Pravastatin Sodium | 62135-847 | Tablet, film coated | Generic drugs (ANDA) | September 26, 2024 |
| SulfADIAZINE | 62135-842 | Tablet | Generic drugs (ANDA) | September 23, 2024 |
| Hyoscyamine sulfate Sublingual | 62135-859 | Tablet | Other unapproved drugs | September 20, 2024 |
| Hyoscyamine sulfate | 62135-858 | Tablet, orally disintegrating | Other unapproved drugs | September 20, 2024 |
| Glycopyrrolate | 62135-961 | Solution | Generic drugs (ANDA) | August 28, 2024 |
| Zolpidem Tartrate | 62135-779 | Tablet | Generic drugs (ANDA) | August 27, 2024 |
| Zolpidem Tartrate | 62135-778 | Tablet | Generic drugs (ANDA) | August 27, 2024 |
| Hyoscyamine sulfate | 62135-860 | Tablet, extended release | Other unapproved drugs | June 5, 2024 |
| Lacosamide Oral Solution | 62135-885 | Solution | Generic drugs (ANDA) | May 15, 2024 |
| Fenofibrate | 62135-899 | Capsule | Generic drugs (ANDA) | January 31, 2024 |
| Fenofibrate | 62135-894 | Capsule | Generic drugs (ANDA) | January 31, 2024 |
| Fenofibrate | 62135-893 | Capsule | Generic drugs (ANDA) | January 31, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.